BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou B, Ji K, Peng A, Yang X, Huang K. GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open Biochem J 2014;8:107-11. [PMID: 25598850 DOI: 10.2174/1874091X01408010107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Maskery MP, Holscher C, Jones SP, Price CI, Strain WD, Watkins CL, Werring DJ, Emsley HC. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J Cereb Blood Flow Metab 2021;41:14-30. [PMID: 32954901 DOI: 10.1177/0271678X20952011] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol 2021;17:227-44. [PMID: 33219281 DOI: 10.1038/s41581-020-00367-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
3 Wang C, Yang C, Chen YC, Ma L, Huang K. Rational Design of Hybrid Peptides: A Novel Drug Design Approach. Curr Med Sci 2019;39:349-55. [PMID: 31209802 DOI: 10.1007/s11596-019-2042-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
4 Przezak A, Bielka W, Pawlik A. Incretins in the Therapy of Diabetic Kidney Disease. Int J Mol Sci 2021;22:12312. [PMID: 34830194 DOI: 10.3390/ijms222212312] [Reference Citation Analysis]